HSP90 and HSP27 inhibitors in breast cancer therapy
A detailed description of HSP90 and HSP27 inhibitors (CNF2024, NVP-
AUY922, retaspimycin, OGX-427) that are currently used in routine
therapy or are in clinical trials in breast cancer patients.
In « Molecular Therapy of Breast Cancer: Classicism Meets Modernity ».
by Marc Lacroix
InTextoResearch, Baelen (Liège, Wallonia), Belgium
Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0